000908.SZ
石药景峰
SZSE · Healthcare · C 制造业 · CN
CNY 6.42
−4.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 385.5M | 378.1M | 416.0M | 656.9M | 840.7M |
| Cost of Revenue | 140.0M | 140.3M | 154.8M | 185.5M | 199.3M |
| Gross Profit | 245.6M | 237.8M | 261.3M | 471.4M | 641.3M |
| Operating Expenses | |||||
| R&D Expense | 11.9M | 11.0M | 13.0M | 52.5M | 35.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 85.6M | 90.0M | 112.7M | 156.4M | 170.6M |
| Selling & Marketing Expense | 167.8M | 164.5M | 137.0M | 347.1M | 421.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 297.2M | 302.8M | 313.2M | 607.6M | 691.8M |
| Cost and Expenses | 437.2M | 443.1M | 467.9M | 793.1M | 891.1M |
| Operating Income (EBIT) | (43.9M) | (58.0M) | 203.9M | (172.9M) | (68.3M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (60.1M) | (77.6M) | 164.5M | (194.6M) | (85.6M) |
| Income Tax Expense | 3.0M | 1.4M | 5.1M | 32.8M | 9.6M |
| Bottom Line | |||||
| Net Income | (65.3M) | (80.9M) | 152.3M | (236.1M) | (122.6M) |
| Earnings from Cont. Ops | (63.2M) | (79.0M) | 159.4M | (261.8M) | (150.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (65.3M) | (80.9M) | 152.3M | (236.1M) | (122.6M) |
| Per Share | |||||
| Basic EPS | (CN¥0.07) | (CN¥0.09) | CN¥0.17 | (CN¥0.27) | (CN¥0.14) |
| Diluted EPS | (CN¥0.07) | (CN¥0.09) | CN¥0.17 | (CN¥0.27) | (CN¥0.14) |
| Revenue Per Share | CN¥0.44 | CN¥0.43 | CN¥0.47 | CN¥0.75 | CN¥0.96 |
| Shares | |||||
| Basic Shares Outstanding | 873.8M | 880.2M | 879.9M | 879.7M | 879.9M |
| Diluted Shares Outstanding | 873.8M | 880.2M | 879.9M | 879.7M | 879.9M |
| Profitability Metrics | |||||
| EBITDA | — | (27.9M) | 230.7M | (131.4M) | (11.7M) |
| D&A | — | 30.1M | 26.8M | 41.5M | 56.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026